Tumour necrosis factor-α and soluble Fas ligand as biomarkers in non-acetaminophen-induced acute liver failure

Biomarkers

Volumn 14, Issue 5, 2009, Pages 347-353

  Singhal, Shashideep ^a   Chakravarty, Anita ^b   Das, Bhudev C ^c   Kar, Premashis ^a  

^a UNIVERSITY OF DELHI   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c Institute for Cytology and Preventive Oncology (ICMR)   (India)

Author keywords

Acute liver failure; Hepatitis E; Non acetaminophen; Soluble Fas ligand; TNF

Indexed keywords

BIOLOGICAL MARKER; FAS LIGAND; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEPATITIS; ADOLESCENT; ADULT; ARTICLE; BRAIN DISEASE; CHILD; CONTROLLED STUDY; CONVALESCENCE; FEMALE; FOLLOW UP; HEPATITIS E; HOSPITAL ADMISSION; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PREDICTION; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TRANSPLANTATION; BLOOD; HEPATITIS; INDIA; SOLUBILITY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; FAS LIGAND PROTEIN; FEMALE; FOLLOW-UP STUDIES; HEPATITIS; HUMANS; INDIA; LIVER FAILURE, ACUTE; MALE; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70149086682     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500903013664     Document Type: Article

References (33)

1. Acharya SK, Dasarathy S, Kumer TL, Sushma S, Prasanna KS, Tandon A, Sreenivas V, Nijhawan S, Panda SK, Nanda SK, Irshad M, Joshi YK, Duttagupta S, Tandon RK, Tandon BN. (1996). Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 23:1448-1455
2. Acharya SK, Panda SK, Saxena A, Gupta SD. (2000). Acute hepatic failure in India: A perspective from the East. J Gastroenterol Hepatol 15:473-479
3. Bernuau J, Rueff B, Benhamou JP. (1986). Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 6:97-106.
4. Bhatia V, Singhal A, Panda SK, Acharya SK. (2008). A 20-year singlecenter experience with acute liver failure during pregnancy: Is the prognosis really worse? Hepatology 48:1577-1585
5. De la Mata M, Meager A, Rolando N, Daniels HM, Nouri-Aria KT, Goka AK, Eddleston AL, Alexander GJ, Williams R. (1990). Tumour necrosis factor production in fulminant hepatic failure: relation to aetiology and superimposed microbial infection. Clin Exp Immunol 82:479-484
6. Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB. (1998). Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 43:1311-1316
7. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. (1995). Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223-1230
8. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. (2002). Mechanisms of hepatotoxicity. Toxicol Sci 65:166-176
9. Kar P, Budhiraja S, Narang A, Chakravarthy A. (1997). Etiology of sporadic acute and fulminant non-A, non-B viral hepatitis in north India. Indian J Gastroenterol 16:43-45
10. Kasahara I, Saitoh K, Nakamura K. (2000). Apoptosis in acute hepatic failure: histopathological study of human liver tissue using the tunel method and immunohistochemistry. J Med Dent Sci 47:167-175
11. Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL, Ascher NL, Roberts JP, Scharschmidt BF, Lake JR. (1992). Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 16:1-7.
12. Nagaki M, Iwai H, Naiki T, Ohnishi H, Muto Y, Moriwaki H. (2000). High levels of serum interleukin-l0 and tumor necrosis factor-? are associated with fatality in fulminant hepatitis. J Infect Dis 182:1103-1108
13. Mita A, Hashikura Y, Tagawa Y, Nakayama J, Kawakubo M, Miyagawa S. (2005). Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am J Gastroenterol 100:2551-2559
14. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. (1988). Enhanced tumour necrosis factor and interleukin- 1 in fulminant hepatic failure. Lancet 9:72-74
15. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364:806-809
16. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. (1989). Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97:439-445 (Pubitemid 19192181)
17. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; US Acute Liver Failure Study Group. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947-954
18. Rivero M, Crespo J, Fabrega E, Casafont F, Mayorga M, Gomez- Fleitas M, Pons-Romero F. (2002). Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat 9:107-113
19. Rust C, Gores GJ. (2000). Apoptosis and liver disease. Am J Med 108:567-574
20. Rutherford A, Hynan LS, Borges CB, Forcione DG, Blackard JT, Lin W, Gorman AR, Shaikh OS, Reuben A, Harrison E, Reddy KR, Le WM, Chung RT; ALF Study Group. (2007). Serum apoptosis markers in acute liver failure: A pilot study. Clin Gastroenterol Hepatol 5:1477-1483
21. Ryo K, Kamogawa Y, Yamauchi K, Hayashi N. (1996). Involvement of Fas and Fas ligand in case of human fulminant hepatitis. Nippon Rinsho 54:1965-1969
22. Ryo K, Kamogawa Y, Ikeda I, Yamauchi K, Yonehara S, Nagata S, Hayashi N (2000). Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 95:2047-2055
23. Sallie R, Silva AE, Purdy M, Smith H, McCaustland K, Tibbs C, Portmann B, Eddleston A, Bradley D, Williams R. (1994). Hepatitis C and E in non-A non-B fulminant hepatic failure: A polymerase chain reaction and serological study. J Hepatol 20:580-588
24. Schiodt FV, Atillasoy E, Shakil AO, Schiff ER, Caldwell C, Kowdley KV, Stribling R, Crippin JS, Flamm S, Somberg KA, Rosen H, McCashland TM, Hay JE, Lee WM. (1999). Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 5:29-34.
25. Sekiyama KD, Yoshiba M, Thomson AW. (1994). Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 98:71-77
26. Singhal S, Jain S, Kohaar I, Singla M, Gondal R, Kar P. (2008). Apoptotic mechanisms in fulminant hepatic failure: Potential therapeutic target. Appl Immunohistochem Mol Morphol Dec 11 [Epub ahead of print].
27. Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, Vergani D, Williams R, Rizzetto M. (1982). Influence of delta infection on severity of Hepatitis B. Lancet 2:945-947
28. Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns M, Trautwein C. (2000). Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 119:446-460
29. Tandon BN, Bernauau J, O'Grady J, Gupta SD, Krisch RE, Liaw YF, Okuda K, Acharya SK. (1999). Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol 14:403-404
30. Tokushige K, Yamaguchi N, Ikeda I, Hashimoto E, Yamauchi K, Hayashi N. (2000). Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am J Gastroenterol 95:2040-2046
31. Trey C, Davidson CS. (1970). The management of fulminant hepatic failure. Prog Liver Dis 3:282-298
32. Vickers C, Neuberger J, Buckels J, McMaster P, Elias E. (1988). Transplantation of the liver in adults and children with fulminant hepatic failure. J Hepatol 7:143-150
33. Wang JY, Wang XL, Liu P. (1999). Detection of serum TNF-alpha, IFN-beta, IL-6 and IL-8 in patients with hepatitis B. World J Gastroenterol 5:38-40.